nach oben

Erschienen in:

15.07.2020 | Hepatobiliary-Pancreas

Does the change in volumetric functional MR metrics post-TACE predict histopathologic grading of hepatocellular carcinoma?

verfasst von: Sanaz Ameli, Mohammadreza Shaghaghi, Mounes Aliyari Ghasabeh, Pallavi Pandey, Bita Hazhirkarzar, Roya Rezvani Habibabadi, Maryam Ghadimi, Pegah Khoshpouri, Ankur Pandey, Ihab R. Kamel

Erschienen in: European Radiology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate whether the change in volumetric ADC (vADC) and volumetric venous enhancement (vVE) after transarterial chemoembolization (TACE) can predict the histologic grading of hepatocellular carcinoma (HCC).

Materials and methods

This HIPPA-compliant retrospective study was approved by our institutional review board. The study population included 106 HCC patients (147 index lesions) who had MR imaging within 3 months before and after TACE and pathologic report of the HCC either by biopsy or liver transplantation/resection between 2001 and 2017. Volumetric measurements of venous enhancement (VE) and apparent diffusion coefficient (ADC) were performed on baseline and post-TACE MRI. The tumors were histologically classified into two low-grade and high-grade groups. The parameters between two groups were compared using bivariate and multivariate analyses.

Results

Median change in vADC, vVE, and absolute vADC skewness after TACE was higher in low-grade HCCs as compared with high-grade HCCs (p < 0.001, p = 0.005, p = 0.04, respectively). Combining ΔvADC, ΔvVE, and the etiology for background liver disease in multivariate analysis had the highest accuracy in distinguishing high-grade tumors (AUC = 91%).

Conclusion

ΔvADC and ΔvVE after TACE are potential predictors of HCC histopathological grading. Combining functional MRI biomarkers with the etiology of liver disease can enhance the accuracy in assessing degree of differentiation.

Key Points

• Change in volumetric functional MRI biomarkers after TACE can be a non-invasive method to evaluate tumor histopathology in HCC.

• The etiology of background liver disease might be a predictor of tumor degree of differentiation.

Jiang T, Xu JH, Zou Y et al (2017) Diffusion-weighted imaging (DWI) of hepatocellular carcinomas: a retrospective analysis of the correlation between qualitative and quantitative DWI and tumour grade. Clin Radiol 72(6):465–472CrossRef

Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250(2):466–473CrossRef

Mannelli L, Kim S, Hajdu CH, Babb JC, Clark TW, Taouli B (2009) Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 193(4):1044–1052CrossRef

Vandecaveye V, Michielsen K, De Keyzer F et al (2013) Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology 270(3):747–757CrossRef

Kamel IR, Bluemke DA, Eng J et al (2006) The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 17(3):505–512CrossRef

Wu XM, Wang JF, Ji JS, Chen MG, Song JG (2017) Evaluation of efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma using magnetic resonance diffusion-weighted imaging. Onco Targets Ther 10:1637–1643CrossRef

Yuan Z, Ye XD, Dong S et al (2010) Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur J Radiol 75(1):e9–e14CrossRef

Mannelli L, Kim S, Hajdu CH, Babb JS, Taouli B (2013) Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol 82(4):577–582CrossRef

Heo SH, Jeong YY, Shin SS et al (2010) Apparent diffusion coefficient value of diffusion-weighted imaging for hepatocellular carcinoma: correlation with the histologic differentiation and the expression of vascular endothelial growth factor. Korean J Radiol 11(3):295–303CrossRef

10.

Nakanishi M, Chuma M, Hige S et al (2012) Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol 19(4):1302–1309CrossRef

11.

Huang K, Dong Z, Cai H et al (2019) Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer 19(1):364CrossRef

12.

Muhi A, Ichikawa T, Motosugi U et al (2009) High-b-value diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma. J Magn Reson Imaging 30(5):1005–1011CrossRef

13.

Kim BK, Han KH, Park YN et al (2008) Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. J Surg Oncol 97(3):246–252CrossRef

14.

Pérez-Saborido B, de los Galanes SJ, Menéu-Díaz JC et al (2007) Tumor recurrence after liver transplantation for hepatocellular carcinoma: recurrence pathway and prognostic factors. Transplant Proc 39(7):2304–2307CrossRef

15.

An C, Park MS, Jeon HM et al (2012) Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI. Eur Radiol 22(8):1701–1708CrossRef

16.

Chen J, Wu M, Liu R, Li S, Gao R, Song B (2015) Preoperative evaluation of the histological grade of hepatocellular carcinoma with diffusion-weighted imaging: a meta-analysis. PLoS One 10(2):e0117661CrossRef

17.

Tamai H (2018) The prediction of microvascular invasion of hepatocellular carcinoma using multiple imaging modalities. Hepatoma Res 4:75

18.

Saito K, Kotake F, Ito N et al (2005) Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 4(1):1–9CrossRef

19.

Kitao A, Zen Y, Matsui O et al (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid–enhanced MR imaging—correlation with molecular transporters and histopathologic features. Radiology 256(3):817–826CrossRef

20.

Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR (2011) Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 260(3):752–761CrossRef

21.

Park IK, Yu JS, Cho ES, Kim JH, Chung JJ (2018) Apparent diffusion coefficient of hepatocellular carcinoma on diffusion-weighted imaging: histopathologic tumor grade versus arterial vascularity during dynamic magnetic resonance imaging. PLoS One 13(5):e0197070CrossRef

22.

Albrecht J, Polenz D, Kühl AA et al (2019) Diffusion-weighted magnetic resonance imaging using a preclinical 1 T PET/MRI in healthy and tumor-bearing rats. EJNMMI Res 9(1):21CrossRef

23.

Shao GL, Zheng JP, Guo LW, Chen YT, Zeng H, Yao Z (2017) Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging. Medicine (Baltimore) 96(3):e5518CrossRef

24.

Mohamed RE, Amin MA, Omar HM (2018) Apparent diffusion coefficient and dynamic contrast-enhanced MRI as reliable biomarkers for evaluating response to locoregional therapy in hepatocellular carcinoma patients. Egypt J Radiol Nucl Med 49(4):914–927CrossRef

25.

Schraml C, Schwenzer NF, Martirosian P et al (2009) Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 193(4):W301–W307CrossRef

26.

Pandey A, Pandey P, Ghasabeh MA et al (2018) Baseline volumetric multiparametric MRI: can it be used to predict survival in patients with unresectable intrahepatic cholangiocarcinoma undergoing transcatheter arterial chemoembolization? Radiology 289(3):843–853CrossRef

27.

Grady L (2006) Random walks for image segmentation. IEEE Trans Pattern Anal Mach Intell 28(11):1768–1783CrossRef

28.

Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 7(3):462–503CrossRef

29.

Kamel IR, Bluemke DA, Ramsey D et al (2003) Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 181(3):708–710CrossRef

30.

Goshima S, Kanematsu M, Kondo H et al (2008) Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization: is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging 27(4):834–839CrossRef

31.

Chapiro J, Wood LD, Lin M et al (2014) Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 273(3):746–758CrossRef

32.

Yao FY, Kerlan RK Jr, Hirose R et al (2008) Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48(3):819–827

33.

Sandow TA, Arndt SE, Albar AA et al (2017) Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort. Radiology 286(3):1072–1083CrossRef

34.

Zarghampour M, Fouladi DF, Pandey A et al (2018) Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors. J Magn Reson Imaging 48(4):1080–1090CrossRef

35.

Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M et al (2018) Prediction of post-TACE necrosis of hepatocellular carcinoma using volumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol 28(7):3032–3040CrossRef

36.

Corona-Villalobos CP, Halappa VG, Geschwind JF et al (2015) Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol 25(2):380–390CrossRef

37.

Mohsen W, Rodov M, Prakoso E et al (2017) Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. World J Gastroenterol 23(15):2763–2770CrossRef

Titel: Does the change in volumetric functional MR metrics post-TACE predict histopathologic grading of hepatocellular carcinoma?
verfasst von: Sanaz Ameli
Mohammadreza Shaghaghi
Mounes Aliyari Ghasabeh
Pallavi Pandey
Bita Hazhirkarzar
Roya Rezvani Habibabadi
Maryam Ghadimi
Pegah Khoshpouri
Ankur Pandey
Ihab R. Kamel
Publikationsdatum: 15.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 12/2020
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-020-07052-9

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Does the change in volumetric functional MR metrics post-TACE predict histopathologic grading of hepatocellular carcinoma?